



### **Organizing Committee Cochairs:**

Patricia M. LoRusso, Yale Cancer Center, New Haven, Connecticut (AACR)<sup>1</sup>  
James H. Doroshow, National Cancer Institute, Bethesda, Maryland (NCI)<sup>1</sup>  
Denis A. Lacombe, European Organisation for Research and Treatment of Cancer, Brussels, Belgium (EORTC)<sup>1</sup>

### **Scientific Committee Cochairs:**

Ryan B. Corcoran, Massachusetts General Hospital, Boston, Massachusetts (AACR)<sup>1</sup>  
Tim F. Greten, National Cancer Institute, Bethesda, Maryland (NCI)<sup>1</sup>  
Elena Garraalda, Vall d'Hebron Institute of Oncology, Barcelona, Spain (EORTC)<sup>1</sup>

### **Scientific Committee Members:**

Rosemarie Aurigemma, NIH-NCI, Rockville, Maryland  
Nilofer S. Azad, Johns Hopkins University, Baltimore, Maryland<sup>1</sup>  
Udai Banerji, The Institute of Cancer Research, London, United Kingdom  
Bristi Basu, University of Cambridge, Cambridge, United Kingdom  
Philippe L. Bedard, University Health Network, Toronto, Ontario, Canada  
Johanna Bendell, Pfizer, Bothell, WA  
Alice P. Chen, National Cancer Institute, Bethesda, Maryland  
Raffaele Colombo, Zymeworks, Inc., Vancouver, British Columbia, Canada  
Natalie Cook, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom  
Benjamin F. Cravatt, The Scripps Research Institute, San Diego, California  
Giuseppe Curigliano, European Institute of Oncology, Milan, Italy  
E.G. Elisabeth de Vries, University Medical Center Groningen, Groningen, Netherlands<sup>1</sup>  
Jaydira Del Rivero, National Cancer Institute, Bethesda, Maryland<sup>1</sup>  
James H. Doroshow, NCI Division of Cancer Treatment and Diagnosis, Bethesda, Maryland  
Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, New York<sup>1</sup>  
Ecaterina E. Dumbrava, The University of Texas MD Anderson Cancer Center, Houston, Texas  
Anna Farago, Amgen Oncology, Thousand Oaks, California  
Elena Garraalda, VHIO Vall D'Hebron Institute of Oncology, Barcelona, Spain  
Steven D. Gore, National Institutes of Health, Baltimore, Maryland  
Lyndsay N. Harris, National Cancer Institute, Rockville, Maryland  
Sara A. Hurvitz, Fred Hutchinson Cancer Center, Seattle, Washington  
S. Percy Ivy, National Cancer Institute, Bethesda, Maryland  
Katrina L. Jackson, C4 Therapeutics, Watertown, Massachusetts  
Peng Jiang, National Cancer Institute, Bethesda, Maryland  
Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, Tennessee  
Stephen Kelsey, Revolution Medicines, Redwood City, California  
Jung-Min Lee, National Cancer Institute, Bethesda, Maryland  
Christophe Massard, Gustave Roussy, Université Paris-Saclay, France  
Victor Moreno, START Madrid, Madrid, Spain  
Ralph E. Parchment, NCI-Frederick/Leidos Biomedical Research, Inc., Frederick, Maryland  
Lilli Petruzzelli, Genentech, Inc., San Francisco, California  
Yves G. Pommier, National Cancer Institute, Bethesda, Maryland  
Victoria Sanchez, VHIO Vall D'Hebron Institute of Oncology, Barcelona, Spain

*\* - oral presentation from proffered paper*



John Schneckloth, National Cancer Institute, Frederick, Maryland  
Patrick Schöffski, Catholic University of Leuven, Leuven Cancer Institute, Leuven, Belgium  
Alison Schram, Memorial Sloan Kettering Cancer Center, Scarsdale, New York  
Lesley K. Seymour, Queen's University, Kingston, Ontario, Canada  
Alexander Spira, Virginia Cancer Specialists, Herndon, Virginia  
Neeltje Steeghs, Netherlands Cancer Institute, Amsterdam, Netherlands  
Vivek Subbiah, Sarah Cannon Research Institute, Nashville, Tennessee  
Stefan N. Symeonides, University of Edinburgh, Edinburgh, Scotland<sup>1</sup>  
Beverly A. Teicher, National Cancer Institute, Rockville, Maryland  
Craig Thomas, National Center for Advancing Translational Sciences, Rockville, Maryland<sup>1</sup>  
Jeanne Tie, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia  
Samra Turajlic, The Francis Crick Institute, London, United Kingdom  
Andreas S. Varkaris, MGH/Harvard Medical School, Boston, Massachusetts  
Mike Waring, Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom  
Jing Wu, National Cancer Institute, Bethesda, Maryland  
Oladapo Yeku, Massachusetts General Hospital, Boston, Massachusetts  
Takayuki Yoshino, National Cancer Center Hospital East, Kashiwa City, Japan

<sup>1</sup> denotes Executive Committee Member

\* - oral presentation from proffered paper



## **WEDNESDAY, OCTOBER 22**

### **Registration**

12-7 pm | Level 2, Lobby D

### **Educational Session 1: Novel Phase I Clinical Trial Designs**

2-3:30 pm | Level 3, Ballroom AB

Session Cochairs: Christophe Massard, Gustave Roussy, Université Paris-Saclay, France, and Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX

2-2:05	Introduction Christophe Massard
2:05-2:25	Strategies to integrate liquid and tumor biopsies in phase I trials Christophe Massard
2:25-2:45	Moving phase 1 trials to first-line metastatic disease: Challenges and opportunities Anna Farago, Amgen Oncology, Thousand Oaks, CA
2:45-3:05	Project Optimus: Novel Phase I clinical trial designs Timothy A. Yap
3:05-3:30	Q&A / Discussion

### **Break**

3:30-3:45 pm

### **Educational Session 2: How to Approach Project Optimus?**

3:45-5:15 pm | Level 3, Ballroom AB

Session Cochairs: Deepa S. Subramaniam, AstraZeneca, Gaithersburg, MD, and Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX

3:45-3:50	Introduction Timothy A. Yap
3:50-4:10	Achieving dosage optimization for combination regimens Deepa S. Subramaniam
4:10-4:30	Project Optimus challenges from the biotech perspective Harpreet Singh, Precision for Medicine, Bethesda, MD
4:30-5:15	Q&A / Discussion

\* - oral presentation from proffered paper



**Additional Discussants:**

Robert Doebele, Boundless Bio, San Diego, CA  
 Anna Farago, Amgen Oncology, Thousand Oaks, CA  
 Patricia M. LoRusso, Yale Cancer Center, New Haven, CT

**Break**

5:15-5:30 pm

**Welcome and Opening Keynote Lectures**

5:30-7:15 pm | Level 3, Ballroom AB

- |           |  |
|-----------|--|
| 5:30-5:40 | Welcome from Scientific Committee Cochairs<br>Ryan B. Corcoran, Massachusetts General Hospital, Boston, MA<br>Elena Garraalda, Vall d'Hebron Institute of Oncology, Barcelona, Spain |
| 5:40-5:45 | Introduction of Keynote Speaker<br>Ryan B. Corcoran, Massachusetts General Hospital, Boston, MA  |
| 5:45-6:15 | Unlocking the potential of bispecific T-cell engagers in solid tumors<br>Jean-Charles Soria, Amgen Oncology, Thousand Oaks, CA   |
| 6:15-6:20 | Introduction of Keynote Speaker<br>Elena Garraalda, Vall d'Hebron Institute of Oncology, Barcelona, Spain  |
| 6:20-6:50 | The coming renaissance of cancer immunotherapy<br>Ira Mellman, Parker Institute for Cancer Immunotherapy, San Francisco, CA  |
| 6:50-7:15 | Q&A / Discussion   |

**Opening Reception**

7:15-9:30 pm | Level 3, Boylston Street Hallway

*\* - oral presentation from proffered paper*



## **THURSDAY, OCTOBER 23**

### **Registration**

7 am-5 pm | Lobby D

### **Continental Breakfast**

7-8 am | Ballroom Foyer and Bolyston Street Hallway

### **Plenary Session 1: Targeting RAS**

8-9:40 am | Level 3, Ballroom AB

Session Chair: David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, TX

8-8:05	Introduction David S. Hong
8:05-8:25	Targeting RAS in pancreatic cancer Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, MA
8:25-8:30	Q&A
8:30-8:50	Targeting the oncogenic state of RAS with tri-complex inhibitors Jan Smith, Revolution Medicines, Redwood City, CA
8:50-8:55	Q&A
8:55-9:15	Targeting RAS: What have we learned? What are we learning? What do we need to learn? David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, TX
9:15-9:20	Q&A
9:20-9:40	Panel Discussion

### **Break**

9:40-10 am

*\* - oral presentation from proffered paper*



## Plenary Session 2: Radiopharmaceuticals

10-11:40 am | Level 3, Ballroom AB

Session Cochairs: Alessandra Gennari, University of Piemonte Orientale, Novara, Italy, and Oliver Sartor, Tulane University School of Medicine, New Orleans, LA

10-10:05	Introduction Oliver Sartor
10:05-10:25	Critical factors in design of ligands useful for molecularly targeted radiation John Babich, Ratio Therapeutics, Boston, MA
10:25-10:30	Q&A
10:30-10:50	Factors important in selection of targets for radiopharmaceuticals H. David Ulmert, University of California, Los Angeles, CA
10:50-10:55	Q&A
10:55-11:15	Bench to bedside in academia: Lessons learned and planning the next generation radiopharmaceuticals Andrei Iagaru, Stanford University, Stanford, CA
11:15-11:20	Q&A
11:20-11:40	Panel Discussion

## Spotlight on Proffered Papers 1: Mechanistic Insights into Targeting the MAPK Pathway

11:45 am-12:15 pm | Level 3, Ballroom AB

Session Chair: Elena Garralda, Vall d'Hebron Institute of Oncology, Barcelona, Spain

11:45-11:52	Resistance mechanisms to monotherapy RAS(ON) multi-selective inhibitor Daraxonrasib (RMC-6236) in RAS mutant PDAC inform therapeutic combination strategies* Ida Aronchik, Revolution Medicines, Redwood City, CA
11:52-11:55	Q&A
11:55-12:02	Directed clonal evolution: Leveraging divergent MAPK inhibitor resistance for convergent hypersensitivity to MAPK hyperactivation* Eunice Cho, The Broad Institute, Cambridge, MA
12:02-12:05	Q&A
12:05-12:12	Leveraging conformation selectivity of MAPK-targeting inhibitors for tumor-selective targeting of RAS-mutant cancers* Poulikos Poulikakos, Icahn School of Medicine at Mount Sinai, New York, NY
12:12-12:15	Q&A

\* - oral presentation from proffered paper



## Exhibit Show

12-4 pm | Level 2, Exhibit Hall D

## Poster Session A

12:30-4 pm | Level 2, Exhibit Hall D

## Keynote Lecture

4:15-5 pm | Level 3, Ballroom AB

- |           |   |
|-----------|---|
| 4:15-4:20 | Introduction<br>Elena Garralda, Vall d'Hebron Institute of Oncology, Barcelona, Spain   |
| 4:20-4:50 | A tale of two biomarkers: Improving outcomes for cancer of unknown primary and recurrent early stage non-small cell lung cancer<br>Caroline Dive, CRUK Manchester Institute, Manchester, United Kingdom |
| 4:50-5    | Q&A / Discussion  |

## Concurrent Sessions 1-3

5-6:40 pm

### CC01: AACR Project GENIE: Powering Drug Discovery Through an International Consortium

Session Chair: Kenneth L. Kehl, Dana-Farber Cancer Institute, Boston, MA  
Level 3, Rooms 302/304

- |           |   |
|-----------|---|
| 5-5:05    | Introduction<br>Kenneth L. Kehl   |
| 5:05-5:25 | Using GENIE data for clinico-genomic research<br>Kenneth L. Kehl  |
| 5:25-5:30 | Q&A   |
| 5:30-5:50 | Off-label targeted therapy utilization in the GENIE BPC datasets<br>Jeremy L. Warner, Legorreta Cancer Center at Brown University, Providence, RI |
| 5:50-5:55 | Q&A   |
| 5:55-6:15 | Using GENIE data to drive oncology target identification and drug development<br>Phillip Beer, Step Pharma, Cambridge, United Kingdom             |
| 6:15-6:20 | Q&A   |
| 6:20-6:40 | Panel Discussion  |

\* - oral presentation from proffered paper



## CC02: Bispecifics/T-cell Engagers

Level 3, Ballroom AB

Session Cochairs: Elena Garralda, Vall d'Hebron Institute of Oncology, Barcelona, Spain and Lillian L. Siu, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

5-5:05	Introduction Lillian L. Siu
5:05-5:25	An affinity and architecture roadmap to impact for precision T cell engagers Alan J. Russell, Amgen, Thousand Oaks, CA
5:25-5:30	Q&A
5:30-5:50	Clinical development of T-cell engagers Ben Tran, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
5:50-5:55	Q&A
5:55-6:15	Bispecifics beyond cell engagers Elena Garralda
6:15-6:20	Q&A
6:20-6:30	Updated safety, efficacy, and biomarker analysis from the Phase I Study of Givastomig, a novel Claudin 18.2/4-1BB bispecific antibody, in Claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)* Samuel Klempner, Massachusetts General Hospital, Boston, MA
6:30-6:35	Q&A

## CC03: Protein Degraders

Session Cochairs: Katrina L. Jackson, C4 Therapeutics, Watertown, MA, and Victor Moreno, START Madrid, Madrid, Spain

Level 3, Ballroom C

5-5:05	Introduction Katrina L. Jackson
5:05-5:25	PROTACS in Oncology, targeted therapy of the future? Victor Moreno
5:25-5:30	Q&A
5:30-5:50	Unveiling the hidden interactome of CRBN molecular glues Katherine Donovan, Dana-Farber Cancer Institute, Boston, MA
5:50-5:55	Q&A
5:55-6:15	Discovery and characterization of a clinical-stage molecular glue degrader of WEE1 kinase, BMS-986463, for the treatment of advanced solid tumors

\* - oral presentation from proffered paper



- 6:15-6:20 Joshua M. Baughman, Bristol Myers Squibb, San Diego CA  
Q&A
- 6:20-6:30 PXG-CycK, a highly selective molecular glue degrader of Cyclin K with  
potent anti-tumor activity in HER2-amplified cancers\*  
Matthias Brand, Proxygen, Vienna, Austria
- 6:30-6:35 Q&A

**AACR Chemistry in Cancer Research Working Group (CICR) Reception and Town Hall:  
The Promise of Molecular Glues in Cancer Treatment – Will it Stick?**

6:45-8:15 pm | Level 3, Rooms 302/304

- 6:45-7:15 Reception (Room 312)
- 7:15-8:15 Town Hall  
Moderator: Daniel La, TRIANA Biomedicines, Lexington, MA

**Panelists:**

Katherine Donovan, Dana-Farber Cancer Institute, Boston, MA  
Jannik N. Anderson, Tango Therapeutics, Boston, MA  
Christopher Nasveschuk, C4 Therapeutics, Watertown, MA

\* - oral presentation from proffered paper



## **FRIDAY, OCTOBER 24**

### **Registration**

7 am-5 pm | Lobby D

### **Continental Breakfast**

7-8 am | Ballroom Foyer and Bolyston Street Hallway

### **Plenary Session 3: Antibody Drug Conjugates**

8-9:45 am | Level 3, Ballroom AB

Session Chair: Raffaele Colombo, Zymeworks, Inc., Vancouver, BC, Canada

8-8:05	Introduction Raffaele Colombo
8:05-8:25	Dual payload ADCs: Twice the excitement, twice the complexity Shawn C. Owen, University of Utah, Salt Lake City, UT
8:25-8:30	Q&A
8:30-8:50	Combining ADCs with targeted therapies: Preclinical rationale for emerging clinical applications Bruna Pellini, H. Lee Moffitt Cancer Center, Tampa, FL
8:50-8:55	Q&A
8:55-9:15	Computational pathology in ADC biomarker development Mark D. Gustavson, AstraZeneca Oncology, Gaithersburg, MD
9:15-9:20	Q&A
9:20-9:30	Phase 1 trial of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer*
9:30-9:35	Grace K. Dy, Roswell Park Comprehensive Cancer Center, Buffalo, NY
	Q&A
9:35-9:45	Panel Discussion

### **Break**

9:45-10 am

### **Plenary Session 4: Clinical Trials Plenary Session**

10-11:40 am | Level 3, Ballroom AB

Session Chair: Ryan B. Corcoran, Massachusetts General Hospital, Boston, MA

10-10:05	Introduction Ryan B. Corcoran
10:05-10:15	A phase 1/2 trial of FOG-001, a first-in-class direct $\beta$ -catenin:TCF4

\* - oral presentation from proffered paper



- inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)\*  
Samuel Klempner, Massachusetts General Hospital, Boston, MA  
Q&A
- 10:15-10:20
- 10:20-10:30 Petosemtamab (MCLA-158) monotherapy or with chemotherapy in metastatic colorectal cancer: Preliminary antitumor activity and safety data from a phase 2 trial\*  
Moh'd Khushman, Washington University School of Medicine, St. Louis, MO  
Q&A
- 10:30-10:35
- 10:35-10:45 Preliminary safety, pharmacokinetics, and antitumor activity of HLD-0915, a first-in-class oral RIPTAC™ binding androgen receptor (AR) and bromodomain 4 (BRD4), in patients with metastatic castrate resistant prostate cancer (mCRPC)\*  
Andrew Hahn, The University of Texas MD Anderson Cancer Center, Houston, TX  
Q&A
- 10:45-10:50
- 10:50-11 Safety and clinical activity of FX-909, a first-in-class oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), a master regulator of luminal lineage in patients with advanced urothelial carcinoma\*  
Xin Gao, Massachusetts General Hospital, Harvard Medical School, Boston, MA  
Q&A
- 11-11:05
- 11:05-11:15 A phase I trial of the MYB RNA degrader REM-422 in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC)\*  
Glenn J. Hanna, Dana-Farber Cancer Institute, Boston, MA  
Q&A
- 11:15-11:20
- 11:20-11:30 Rezatapopt for locally advanced or metastatic solid tumors with a TP53 Y220C mutation: Initial analysis of the pivotal PYNACLE Phase 2 trial\*  
Alison Schram, Memorial Sloan Kettering Cancer Center, New York, NY  
Q&A
- 11:30-11:35

### Spotlight on Proffered Papers 2: Clinical Advances in Targeting KRAS

11:45 am-12:15 pm | Level 3, Ballroom AB

Session Chair: Ryan B. Corcoran, Massachusetts General Hospital, Boston, MA

- 11:45-11:52 Efficacy and safety of ASP3082, a novel protein degrader, as monotherapy in patients (pts) with non-small cell lung cancer (NSCLC) with KRAS G12D mutation\*

\* - oral presentation from proffered paper



- |             |   |
|-------------|---|
|             | Alexander Spira, Virginia Cancer Specialists and NEXT Oncology-Virginia, Fairfax, VA  |
| 11:52-11:55 | Q&A   |
| 11:55-12:02 | Efficacy and safety of Elironrasib, a RAS(ON) G12C-selective inhibitor, in patients with KRAS G12C NSCLC following treatment with a KRAS(OFF) G12C inhibitor*   |
|             | Bruna Pellini, H. Lee Moffitt Cancer Center, Tampa, FL  |
| 12:02-12:05 | Q&A   |
| 12:05-12:12 | A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring allosteric KRAS inhibitor, in patients with solid tumors with <i>KRAS</i> <sup>G12D</sup> mutation* |
|             | Ignacio Garrido-Laguna, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT   |
| 12:12-12:15 | Q&A   |

### Exhibit Show

12-4 pm | Level 2, Exhibit Hall D

### Poster Session B

12:30-4 pm | Level 2, Exhibit Hall D

### Concurrent Sessions 4-6

4:15-6 pm

#### CC04: Cancer Vaccines

Session Cochairs: Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, NY, and Stephane Champiat, The University of Texas MD Anderson Cancer Center, Houston, TX  
Level 3, Ballroom AB

- |           |  |
|-----------|--|
| 4:15-4:20 | Introduction<br>Vinod P. Balachandran  |
| 4:20-4:38 | Personalized cancer vaccines: Challenges, progress, and opportunities<br>Patrick Ott, Dana-Farber Cancer Institute, Boston, MA |
| 4:38-4:42 | Q&A  |
| 4:42-5    | Personalized vaccines for pancreatic cancer<br>Vinod P. Balachandran   |
| 5-5:04    | Q&A  |
| 5:04-5:22 | in-situ Vaccination<br>Stephane Champiat   |
| 5:22-5:26 | Q&A  |

\* - oral presentation from proffered paper



- 5:26-5:33      Neoadjuvant PD-1 blockade combined with therapeutic DNA vaccine and IL-7 reshapes intratumoral immunity in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC)\*  
June-Young Koh, University of California San Diego, San Diego, CA
- 5:33-5:36      Q&A
- 5:36-6          Panel Discussion

### **CC05: Emerging Targets in Development**

Session Cochairs: Joanna Loizou, Institute of Cancer Research, London, England, and Yves G. Pommier, National Cancer Institute, Bethesda, MD  
Level 3, Rooms 302/304

- 4:15-4:20      Introduction  
Joanna Loizou
- 4:20-4:38      Rational combinations with tumor-targeted anticancer agents based on pharmacokinetics and pharmacodynamic biomarkers  
Yves G. Pommier
- 4:38-4:42      Q&A
- 4:42-5          Maximizing ATR inhibitor clinical benefit: defining novel biomarkers of response and overcoming compensatory resistance mechanisms  
Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA
- 5-5:04          Q&A
- 5:04-5:22      The anion transporter GPR89 is an actionable tumour-specific dependency in breast cancer  
Joanna Loizou
- 5:22-5:26      Q&A
- 5:26-5:33      Discovery of an allosteric, potent and selective DHX9 helicase inhibitor with best-in-class potential for the treatment of genomically unstable cancers\*  
Taran Khanam, Storm Therapeutics, Cambridge, United Kingdom
- 5:33-5:36      Q&A
- 5:36-6          Panel Discussion

### **CC06: Novel Approaches in Small Molecule Development**

Session Cochairs: Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY, and Zoran Rankovic, The Institute of Cancer Research, London, United Kingdom  
Level 3, Ballroom C

\* - oral presentation from proffered paper



4:15-4:20	Introduction Alexander Drilon
4:20-4:38	Mutant selective inhibitors: A clinical perspective Alexander Drilon
4:38-4:42	Q&A
4:42-5	An omics approach to drug discovery Liron Bar-Peled, Massachusetts General Hospital, Charlestown, MA
5-5:04	Q&A
5:04-5:22	Large-scale exploration of the cereblon neosubstrate space for targeted oncoprotein degradation Zoran Rankovic
5:22-5:26	Q&A
5:26-5:33	RAS-mutant tumor-selective inhibition of dimeric RAF by a novel Type 1 RAF inhibitor* Mathieu Desautay, Icahn School of Medicine at Mount Sinai, New York, NY
5:33-5:36	Q&A
5:36-6	Panel Discussion

\* - oral presentation from proffered paper



## **SATURDAY, OCTOBER 25**

### **Registration**

7 am-5 pm | Lobby D

### **Continental Breakfast**

7-8 am | Ballroom Foyer and Bolyston Street Hallway

### **Plenary Session 5: Artificial Intelligence and Data Science in Drug Development**

*Supported by the Margaret Foti Foundation*

8-9:40 am | Level 3, Ballroom AB

Session Chair: Vivek Subbiah, Sarah Cannon Research Institute, Nashville, TN

8-8:05	Introduction Vivek Subbiah
8:05-8:25	New AI tools for drug discovery Regina Barzilay, Massachusetts Institute of Technology, Cambridge, MA
8:25-8:30	Q&A
8:30-8:50	Blueprints for the future: AI-guided precision oncology trials Vivek Subbiah
8:50-8:55	Q&A
8:55-9:15	AI, Antibody-Drug Conjugates, and target expression Siraj Ali, Lunit, Boston, MA
9:15-9:20	Q&A
9:20-9:40	Panel Discussion

### **Break**

9:40-10 am

*\* - oral presentation from proffered paper*



## Plenary Session 6: Novel Epigenetic Targets

10-11:40 am | Level 3, Ballroom AB

Session Chair: Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD

- |             |   |
|-------------|---|
| 10-10:05    | Introduction<br>Stephen B. Baylin   |
| 10:05-10:25 | A new epigenetic therapy strategy to reverse cancer specific DNA methylation abnormalities<br>Stephen B. Baylin         |
| 10:25-10:28 | Q&A   |
| 10:28-10:48 | Novel epigenetic targets in leukemia<br>Irmela Jeremais, Helmholtz Center, Munich, Germany                              |
| 10:48-10:51 | Q&A   |
| 10:51-11:11 | DNA replication and cell identity<br>Constance Alabert, University of Dundee, Dundee, Scotland                          |
| 11:11-11:14 | Q&A   |
| 11:14-11:21 | PF-07248144 – First-in-class potent, selective KAT6i in ER+HER2–breast cancer*<br>Shikhar Sharma, Pfizer, San Diego, CA |
| 11:21-11:24 | Q&A   |
| 11:24-11:40 | Panel Discussion  |

## Spotlight on Proffered Papers 3: Novel Therapeutic Agents

11:45 am-12:15 pm | Level 3, Ballroom AB

Session Chair: Elena Garralda, Vall d'Hebron Institute of Oncology, Barcelona, Spain

- |             |  |
|-------------|--|
| 11:45-11:52 | Discovery and characterization of a highly potent and orally available SMARCA2 PROTAC degrader*<br>Haiyan Ying, Abbisko Therapeutics, Shanghai, China  |
| 11:52-11:55 | Q&A  |
| 11:55-12:02 | Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window*<br>Archie Tse, Adlai Nortye Ltd., Hangzhou, China |
| 12:02-12:05 | Q&A  |
| 12:05-12:12 | A STAT3 PROTAC degrader SD-1240: The structure-based design, the structure mechanism of potency and selectivity, and the mechanism of action of anti-tumor activity*<br>Haibin Zhou, University of Michigan, Ann Arbor, MI         |

\* - oral presentation from proffered paper



12:12-12:15 Q&A

## Exhibit Show

12-4 pm | Level 2, Exhibit Hall D

## Poster Session C

12:30-4 pm | Level 2, Exhibit Hall D

## Concurrent Sessions 7-9

4:15-6 pm

### CC07: Novel Endpoints

Session Chair: Philippe L. Bedard, University Health Network, Toronto, ON, Canada  
Level 3, Ballroom AB

- |           |   |
|-----------|---|
| 4:15-4:20 | Introduction<br>Philippe L. Bedard  |
| 4:20-4:40 | ctDNA/MRD guided endpoints<br>Philippe L. Bedard  |
| 4:40-4:45 | Q&A   |
| 4:45-5:05 | Capturing the patient voice: Integrating PROs into early phase oncology trials<br>Christina Yap, Institute for Cancer Research, London, England |
| 5:05-5:10 | Q&A   |
| 5:10-5:30 | PET imaging endpoints in phase 1/2 clinical trials<br>Shadi Abdar Esfahani, Massachusetts General Hospital, Boston, MA                          |
| 5:30-5:35 | Q&A   |
| 5:35-6    | Panel Discussion  |

### CC08: Pediatric and Rare Cancers

Session Cochairs: Mariella G. Filbin, Dana-Farber Cancer Institute, Boston, MA, and  
Rodrigo de Almeida Toledo, Vall d'Hebron Institute of Technology, Barcelona, Spain  
Level 3, Rooms 302/304

- |           |   |
|-----------|---|
| 4:15-4:20 | Introduction<br>Mariella G. Filbin  |
| 4:20-4:40 | Targeting developmental programs in pediatric high-grade glioma<br>Mariella G. Filbin |
| 4:40-4:45 | Q&A   |
| 4:45-5:05 | Accelerating breakthroughs in rare cancer treatment through                           |

\* - oral presentation from proffered paper



	academic–industry partnerships Rodrigo de Almeida Toledo
5:05-5:10	Q&A
5:10-5:30	Decoding neuroendocrine tumour heterogeneity through AI-driven clinical phenotypes and multiomics integration Anguraj Sadanadam, The Institute of Cancer Research, London, United Kingdom
5:30-5:35	Q&A
5:35-5:45	Zenocutuzumab efficacy and safety in advanced NRG1+ cholangiocarcinoma: Analysis from the phase 2 eNRGy trial* Alison Schram, Memorial Sloan Kettering Cancer Center, Scarsdale, NY
5:45-6	Panel Discussion

### **CC09: Targeting RNA with Small Molecules**

Session Cochairs: Christopher J. Bowden, Remix Therapeutics, Watertown, MA, and Christopher Burge, Massachusetts Institute of Technology, Cambridge, MA

Level 3, Ballroom C

4:15-4:20	Introduction Christopher Burge
4:20-4:40	REM-422, a first-in-class mRNA degrader of the MYB oncogene Charles Kung, Remix Therapeutics, Watertown, MA
4:40-4:45	Q&A
4:45-5:05	Novel oncology targets for tumors with genomic instability Serena J. Silver, Accent Therapeutics, Lexington, MA
5:05-5:10	Q&A
5:10-5:30	Predicting splicing with black box and interpretable models Christopher Burge
5:30-5:35	Q&A
5:35-6	Panel Discussion

\* - oral presentation from proffered paper



## **SUNDAY, OCTOBER 26**

### **Registration**

7 am-1 pm | Lobby D

### **Continental Breakfast**

7-8 am | Ballroom Foyer and Bolyston Street Hallway

### **Plenary Session 7: Cellular and Adoptive Therapy**

8-9:40 am | Level 3, Ballroom AB

Session Cochairs: Marco Donia, Copenhagen University Hospital, Herlev, Denmark and Matthew Frigault, Massachusetts General Hospital, Boston, MA

8-8:05	Introduction Matthew Frigault
8:05-8:25	Tumor-Infiltrating Lymphocyte therapy in 2025: State of the art and what's next Marco Donia
8:25-8:35	Q&A
8:35-8:55	The role of IFN $\gamma$ in IEC: Is it needed? Depends... Matthew Frigault
8:55-9:05	Q&A
9:05-9:15	Transposon-based BAFF CAR-T cells (LMY-920) for treatment of Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Lymphoma (CLL), and Multiple Myeloma (MM)* Paolo Caimi, Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, OH
9:15-9:20	Q&A
9:20-9:40	Panel Discussion

### **Break**

9:40-10 am

### **Plenary Session 8: Synthetic Lethality**

10-11:45 am | Level 3, Ballroom AB

Session Cochairs: Adam S. Crystal, Tango Therapeutics, Boston, MA, and Victoria Sánchez Perez, Vall D'Hebron Institute of Oncology, Barcelona, Spain

10-10:05	Introduction Victoria Sánchez Perez
----------	--

*\* - oral presentation from proffered paper*



- |             |   |
|-------------|---|
| 10:05-10:23 | PELO-HBS1L: ribosome rescue and mRNA decay as a novel synthetic lethal axis<br>Edmond M. Chan, Columbia University Irving Medical Center, New York, NY  |
| 10:23-10:26 | Q&A   |
| 10:26-10:44 | DNA repair processing and synthetic lethality<br>Peter S. Hammerman, MoMa Therapeutics, Cambridge, MA   |
| 10:44-10:47 | Q&A   |
| 10:47-11:05 | Synthetic lethality beyond DDR pathway<br>Francisca Vazquez, Broad Institute, Cambridge, MA   |
| 11:05-11:08 | Q&A   |
| 11:08-11:26 | PRMT5: Bench to bedside<br>Adam S. Crystal  |
| 11:26-11:29 | Q&A   |
| 11:29-11:36 | A pan-cancer map of paralog dependencies reveals novel synthetic lethal targets and biomarker-defined vulnerabilities*<br>William Sellers, Broad Institute, Dana-Farber Cancer Institute, Harvard Medical School, Cambridge, MA |
| 11:36-11:39 | Q&A   |

### Break

11:45 am-12 pm

### Plenary Session 9: Omics to Guide Precision Therapy

12-1:40 pm | Level 3, Ballroom AB

Session Chair: Peter Horak, German Cancer Research Center, Heidelberg, Germany

- |             |  |
|-------------|--|
| 12-12:05    | Introduction<br>Peter Horak  |
| 12:05-12:25 | The road to implementation of Personalised Cancer Medicine in Europe: DRUP-like clinical trials, PCM-4EU, PRIME-ROSE and the Joint Action on PCM<br>Hans Gelderblom, Leiden University Medical Centre, Leiden, The Netherlands |
| 12:25-12:30 | Q&A  |
| 12:30-12:50 | Rare cancers, tumor agnostic therapies, and real world data<br>David M. Thomas, University of New South Wales, Sydney, NSW, Australia  |
| 12:50-12:55 | Q&A  |

\* - oral presentation from proffered paper



- |            |   |
|------------|---|
| 12:55-1:15 | Integrative multi-omics profiling identifies therapeutic opportunities in rare tumors |
|            | Peter Horak   |
| 1:15-1:20  | Q&A   |
| 1:20-1:40  | Panel Discussion  |

**Closing Comments and Departure**

1:40 pm-1:45 pm | Level 3, Ballroom AB

\* - oral presentation from proffered paper